Recurrent Breast Cancer Completed Phase 1 Trials for Bavituximab (DB05136)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01288261Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast CancerTreatment